Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to new results. This analysis in more than 1 250 patients ...

The trial did not meet its primary end point for reducing plaque progression. The National Institutes of Health–funded CAVIAR—Cardiac Allograft Vasculopathy Inhibition with AliRocumab—trial included ...

Alirocumab, a PCSK9 inhibitor approved for lowering LDL cholesterol levels, will remain available in the US, at least for now, after an appeals court issued a stay of the permanent injunction that had ...

Sanofi and Regeneron announced positive results from four Phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting ...

Please provide your email address to receive an email when new articles are posted on . Alirocumab plus high-intensity statin therapy improved coronary plaque burden in patients with familial ...

Please provide your email address to receive an email when new articles are posted on . Two studies presented at the virtual American College of Cardiology Scientific Session highlight new options for ...

CHICAGO, IL—If the PCSK9 inhibitor alirocumab (Praluent; Sanofi/Regeneron) is to be considered cost-effective by current willingness-to-pay standards, the drug needs to be priced at approximately ...

Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, was found to be both safe and effective in reducing low-density lipoprotein cholesterol (LDL-C) in patients with ...

The appraisal committee considered evidence submitted by Sanofi and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

The cholesterol-lowering drug alirocumab (Praluent) will be available at a new list price of $5850 a year for the 75 mg and 150 mg doses beginning in early March, according to Sanofi and partner ...

NEW ORLEANS – A substantial part of the cardiac-event risk decline seen in patients taking alirocumab (Praluent, Sanofi/Regeneron) in the ODYSSEY Outcomes trial can be attributed to reductions in ...